obesity

Immune cells drive beta cell loss in Type 2 diabetes

Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.

Inflammatory driver of obesity

Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.

From left, Raymond C. Harris, MD, Shirong Cao, MD, PhD, Ming-Zhi Zhang, MD, MSc, and colleagues are studying the role of inflammation in obesity.

Study sheds light on the dark side of obesity

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

Reducing obesity-related inflammation

A treatment that increases levels of lipid signaling molecules reduced adipose tissue inflammation in obese adults, suggesting this pathway may be a valuable target for modulating fat and systemic inflammation.

New insights into hypothalamic obesity

A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report.

Regulators of fat cell metabolism

Vanderbilt researchers have discovered new details of the regulation of fat cell metabolism, findings that are important for combating obesity.

1 2 3 4 7